Scinai Immunotherapeutics (SCNI) FCF Margin (2024)

Scinai Immunotherapeutics' (SCNI) quarterly FCF Margin came in at 533.98% in Q4 2024, up 55.9% quarter-over-quarter from 1210.71% in Q3 2024.

Scinai Immunotherapeutics (SCNI) FCF Margin (2024) Analysis & Trends

Scinai Immunotherapeutics has disclosed FCF Margin across 1 years of filings, most recently posting 533.98% for Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -3.98%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 43.35%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Scinai Immunotherapeutics 3.02 Bn 988.23 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 -533.98%
Sep 30, 2024 -1,210.71%